Peptide News Digest

ADA 2026 Day 1: Structure Aleniglipron Nature Medicine + Oral, CagriSema REIMAGINE 2 14.2% T2D, MetaVia DA-1726 32mg, Hengrui HRS-7535 Phase 3, Survodutide SYNCHRONIZE-1, Lexicon Sotagliflozin

ADA opens: Structure aleniglipron in Nature Medicine, CagriSema REIMAGINE 2 14.2% T2D loss, survodutide SYNCHRONIZE-1, Hengrui HRS-7535, MetaVia, Lexicon.

10 stories · Covering clinical-trials, industry

Editor's Note

The American Diabetes Association meeting opened in New Orleans with the year's broadest metabolic-peptide slate, and the late-breaker embargo lifted at 6:30 p.m. local. Two stories anchored Day 1. Structure Therapeutics published full Phase 2b aleniglipron data in Nature Medicine and presented it in a 12:45 p.m. oral session, the cleanest case yet that an oral small-molecule GLP-1 can match injectables. Novo Nordisk's REIMAGINE 2 readout for CagriSema in type 2 diabetes added a 1.91-point HbA1c drop and 14.2% weight loss versus semaglutide alone, the first head-to-head Phase 3 data for the dual agonist. Behind those, the Chinese pipeline kept advancing (Hengrui's oral HRS-7535 cleared its Phase 3 in T2D), MetaVia added higher-dose DA-1726 detail, survodutide's full SYNCHRONIZE-1 obesity numbers landed, and Roche queued petrelintide and enicepatide for Monday. The retatrutide and orforglipron symposia are still ahead.

Clinical Trials

Structure Therapeutics Aleniglipron Hits Day 1 of ADA With Simultaneous Nature Medicine Publication and Full Phase 2b ACCESS Oral Presentation

Nature Medicine published Structure's Phase 2b ACCESS trial of aleniglipron, the once-daily oral small-molecule GLP-1, on June 5, with lead author Julio Rosenstock presenting the full data in a 12:45 p.m. CT oral session at ADA 2026 the same afternoon. The 44-week ACCESS II readout reached up to 16.3% placebo-adjusted weight loss, the strongest oral GLP-1 number outside Lilly's, and Structure plans to start Phase 3 in Q3 2026 with a 2.5 mg starting dose after end-of-Phase-2 FDA alignment.

#structure-therapeutics #aleniglipron #oral-glp-1 #access #nature-medicine #ada-2026
Clinical Trials

Novo Nordisk CagriSema REIMAGINE 2 Phase 3 in Type 2 Diabetes: 1.91-Point HbA1c Reduction and 14.2% Weight Loss, Beating Semaglutide Alone

At ADA 2026, Novo Nordisk reported full Phase 3 REIMAGINE 2 data for CagriSema (cagrilintide plus semaglutide fixed-dose combination) in 2,728 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor. Over 68 weeks, CagriSema 2.4 mg/2.4 mg produced superior HbA1c reduction of 1.91 percentage points and 14.2% mean weight loss, both better than the semaglutide 2.4 mg, cagrilintide 2.4 mg, and placebo comparator arms. The readout is the first head-to-head Phase 3 win for the dual amylin/GLP-1 combination over its individual components.

#novo-nordisk #cagrisema #reimagine-2 #type-2-diabetes #amylin #cagrilintide #ada-2026
Clinical Trials

Boehringer Survodutide Full SYNCHRONIZE-1 Phase 3 Obesity Data Lands at ADA 2026: 16.6% Weight Loss at 76 Weeks, 85.1% Reaching 5%

Boehringer Ingelheim and Zealand Pharma presented the full Phase 3 SYNCHRONIZE-1 readout for survodutide, the glucagon/GLP-1 dual agonist, at ADA 2026. In adults with obesity or overweight without type 2 diabetes, survodutide produced up to 16.6% mean weight loss at 76 weeks versus 3.2% placebo (p<0.0001), with up to 85.1% achieving at least 5% loss. Analyst attention now turns to body composition and liver-fat substudies, with reductions driven largely by fat-tissue loss rather than lean mass.

#survodutide #boehringer-ingelheim #zealand-pharma #synchronize-1 #obesity #glp-1-glucagon #ada-2026
Clinical Trials

Hengrui's Oral GLP-1 HRS-7535 Clears Phase 3 in Chinese Type 2 Diabetes; NDA Filing Planned

Kailera Therapeutics and Hengrui Pharma reported positive topline Phase 3 data from a Chinese T2D trial of HRS-7535, an oral small-molecule GLP-1 receptor agonist licensed to Kailera. Most adverse events were mild-to-moderate GI, with no Grade 3 hypoglycemic events and no liver-safety signal. Hengrui plans to submit a Chinese NDA for HRS-7535 in T2D and will share detailed efficacy data at an upcoming scientific conference. The readout extends the China-led oral-GLP-1 pipeline alongside ribupatide and aleniglipron.

#hengrui #kailera-therapeutics #hrs-7535 #oral-glp-1 #type-2-diabetes #china
Clinical Trials

MetaVia DA-1726 Phase 1 Higher-Dose Data Lands at ADA With Vanoglipel Combination Posters in MASH and Diabetes

MetaVia's three June 7 posters at ADA cover the higher-dose Part 3 cohort of its once-weekly dual GLP-1/glucagon agonist DA-1726, which previously cleared a 32 mg dose with strong weight, glucose, and waist effects in the multiple-ascending-dose study, and two combinations of its GPR119 agonist vanoglipel: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit. The company is small-cap but its readouts add depth to both the dual-agonist and GPR119 threads.

#metavia #da-1726 #vanoglipel #gpr119 #mash #ada-2026
Clinical Trials

Lexicon Brings Sotagliflozin Subgroup Data in Type 1 Diabetes and Pilavapadin in Diabetic Neuropathic Pain to ADA 2026

Lexicon Pharmaceuticals will present on Sunday, June 7 at ADA 2026: a pooled inTandem subgroup analysis of sotagliflozin, a dual SGLT-1/SGLT-2 inhibitor, in adults with type 1 diabetes (M. Belinda Hardin), and a Phase 1 study of the non-opioid pain candidate pilavapadin in patients with diabetic peripheral neuropathic pain across renal function levels (Rodica Pop-Busui). Lexicon's slate is the meeting's reminder that the diabetes pharmacology field extends beyond incretins.

#lexicon-pharmaceuticals #sotagliflozin #type-1-diabetes #pilavapadin #diabetic-neuropathic-pain #ada-2026
Industry

Genentech Queues Petrelintide ZUPREME-1 and Enicepatide CT388-103 for Monday Investor Event at ADA 2026

Genentech, Roche's US arm, will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide and Phase 2 CT388-103 data for the GLP-1/GIP agonist enicepatide as late-breakers at ADA 2026, with a June 8 virtual investor event. The Roche obesity package combines the two peptides as a planned fixed-dose Phase 2 combination later this year, and the company has projected $9 billion in peak annual sales for the combined pipeline.

#genentech #roche #enicepatide #ct388-103 #petrelintide #ada-2026
Industry

Alnylam and Inceptive Sign Up to $2 Billion AI-Peptide Discovery Partnership

On June 4, 2026, Alnylam Pharmaceuticals announced a partnership worth up to $2 billion with Inceptive, the AI biotech focused on programmable RNA and peptide medicines, to apply machine learning to peptide discovery. The deal is the second major back-loaded peptide-AI collaboration to land in the same week, following Regeneron's expanded Parabilis tie-up tied to Phase 3 LAG-3 setbacks.

#alnylam #inceptive #ai-drug-design #peptide-discovery #partnership #machine-learning
Clinical Trials

Cybrexa Therapeutics Advances Peptide-Drug Conjugate CBX-12 in Platinum-Resistant Ovarian Cancer After Phase 1 Completion

Cybrexa Therapeutics' CBX-12, a 26-amino-acid pH-targeted peptide-drug conjugate that delivers a topoisomerase-1 inhibitor selectively to the acidic tumor microenvironment, completed Phase 1 in September 2024 and has moved into Phase 2 for platinum-resistant ovarian cancer. The peptide-drug conjugate field continues to broaden beyond the bicyclic-peptide and FAP-activated approaches already covered at ASCO, with smaller direct-acting peptide carriers gaining traction.

#cybrexa-therapeutics #cbx-12 #peptide-drug-conjugate #ovarian-cancer #ph-targeted #tumor-microenvironment
Industry

ADA 2026 Day 1 Opens in New Orleans: Lilly Retatrutide Symposium Saturday June 6, Orforglipron ACHIEVE Monday June 8, Roche and Novo Investor Events the Same Day

The 86th ADA Scientific Sessions opened June 5 in New Orleans with the late-breaker embargo lifting at 6:30 p.m. CT. Saturday's June 6 Phase 3 retatrutide symposium brings full TRIUMPH-1 (28.3% mean weight loss at 80 weeks) and TRANSCEND-T2D-1 data; Monday's June 8 orforglipron ACHIEVE symposium covers head-to-head data against oral semaglutide and dapagliflozin; Roche, Novo Nordisk, and Boehringer all run investor events the same day.

#ada-2026 #retatrutide #triumph-1 #orforglipron #achieve #new-orleans